Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 21Gastrointestinal 10NET 9Genitourinary 4Breast 3Thoracic 2Plasma cell 2Lymphoid 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Primary Inoperable Thymoma 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
pasireotide × Thoracic × Clear all
NCT02021942 2018-02-05

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

University of Regensburg

Phase 2 Completed
16 enrolled 11 charts
Thoracic

Primary Inoperable Thymoma

NCT01417806 2011-08-16

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

South Florida Veterans Affairs Foundation for Research and Education

Phase 2 Unknown
28 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡